Development of Drug for Ulcerative Colitis to Be Discontinued, Company Reports

Development of Drug for Ulcerative Colitis to Be Discontinued, Company Reports
Belgium-based Galapagos NV has announced it is discontinuing its clinical development of drug candidate GLPG1205 for ulcerative colitis because an important part of the clinical trial -- endpoints for efficacy -- were not met. The ORIGIN Phase 2a clinical trial with GLPG1205 in patients with ulcerative colitis received good feedback on pharmacokinetics, tolerability, and safety, the company reported in a press release. But the important efficacy endpoints of the trial were not met, leading Galapagos to discontinue clinical development. The company said it will decide whether to develop the drug i
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *